Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | New treatments for AML using inhibitors

Francesco Lo-Coco • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia General

This is an exciting time for acute myeloid leukemia (AML) treatment, with multiple new therapies being investigated currently. In this interview, Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy discusses recent research using inhibitors for the treatment of AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Francesco Lo-Coco

Targeted treatments for AML: the revolution
3:58
Targeted treatments for AML: the revolution
Francesco Lo-Coco • 10 Dec 2017
Advancements in APL treatment: oral ATO, MRD and treatment objectives
3:41
Advancements in APL treatment: oral ATO, MRD and treatment objectives
Francesco Lo-Coco • 10 Dec 2017
APL: getting the perfect picture
2:06
APL: getting the perfect picture
Francesco Lo-Coco • 10 Dec 2017
The standardization of molecular diagnostics for myeloid diseases in Italy
1:57
The standardization of molecular diagnostics for myeloid diseases in Italy
Francesco Lo-Coco • 5 Oct 2017

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals